HC Wainwright & Co. Assumes Milestone Pharmaceuticals at Buy, Announces Price Target of $5
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Brandon Folkes assumes Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and announces Price Target of $5.
HC Wainwright & Co. analyst Brandon Folkes assumes Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and announces Price Target of $5.